Von Willebrand disease (VWD) is not an autoimmune condition. It is a genetic bleeding disorder, inherited from one or both parents, caused by mutations that affect a key blood-clotting protein. However, there is a separate, much rarer condition called acquired von Willebrand syndrome that can be triggered by autoimmune activity. The two look similar on lab tests and share symptoms, but they have fundamentally different causes.
Why VWD Is Genetic, Not Autoimmune
VWD affects up to 1% of the general population, making it the most common inherited bleeding disorder. It occurs equally in men and women. The root cause is a change in the gene responsible for producing von Willebrand factor (VWF), a protein that plays two critical roles in stopping bleeding: it helps platelets stick to damaged blood vessel walls to form a plug, and it stabilizes another clotting protein (factor VIII) so it isn’t cleared from the bloodstream too quickly. Without enough functional VWF, both of these processes falter.
The disease passes from parent to child in predictable patterns. Type 1 and most forms of type 2 VWD are autosomal dominant, meaning a mutation in just one copy of the gene is enough to cause the disorder. Type 3 and type 2N are autosomal recessive, requiring mutations in both copies. None of these types involve the immune system attacking the body’s own proteins. The problem is baked into the genetic instructions for making VWF from birth.
The Acquired Form With Autoimmune Links
Acquired von Willebrand syndrome (AVWS) is a different condition that mimics the inherited disease but develops later in life in people with no family history of bleeding problems. It is rare and widely considered underdiagnosed. Unlike genetic VWD, AVWS has no mutation behind it. Instead, something in the body starts interfering with VWF after it has been produced normally.
One of the main mechanisms is autoimmune: the body generates antibodies that bind to VWF, either neutralizing its function or accelerating its removal from the bloodstream. This immune-driven process is most commonly seen in people with lymphoproliferative disorders (cancers or abnormalities of immune cells) and autoimmune diseases. Lymphoproliferative conditions account for roughly 48% of AVWS cases, with a specific condition called monoclonal gammopathy of unknown significance (MGUS) being the single most common trigger, found in about 23% of registered patients. In MGUS, abnormal proteins produced by immune cells bind directly to VWF, causing the body to clear it faster than normal.
Not every case of AVWS is autoimmune, though. Other mechanisms include mechanical destruction of VWF under high blood flow stress (as seen in certain heart valve conditions), increased breakdown by enzymes, and absorption of VWF onto the surface of abnormal cells. The condition has also been linked to thyroid disorders, certain cancers, and even specific medications.
How the Two Conditions Differ Clinically
The symptoms of inherited VWD and acquired VWS overlap significantly: easy bruising, frequent nosebleeds, heavy menstrual periods, and prolonged bleeding after surgery or injury. The key differences are timing and context. Inherited VWD typically shows up in childhood or adolescence, and there is usually a family history of bleeding problems. Acquired VWS appears later in life, often in middle-aged or older adults, with no prior bleeding history.
Severity can also differ depending on the underlying cause. Patients whose AVWS is linked to lymphoproliferative disorders tend to have more severe bleeding than those with other triggers. When factor VIII levels drop significantly (because VWF is no longer there to stabilize it), the bleeding pattern can start to resemble hemophilia A, with deeper tissue bleeding rather than just surface-level bruising.
Telling Them Apart in the Lab
Standard clotting tests often look identical in both conditions, which is part of why acquired VWS is so frequently missed. One useful tool is measuring the ratio between VWF propeptide (a fragment released when VWF is first made) and the VWF circulating in the blood. In inherited VWD caused by certain mutations, this ratio is elevated because the body produces VWF normally but clears it too fast. A ratio above 3 has a 98% positive predictive value for identifying a true genetic VWF mutation, with 99% specificity. Healthy individuals typically have a ratio around 1.2.
Beyond lab ratios, the absence of a family bleeding history, a late onset of symptoms, and the presence of an associated condition like a blood cancer or autoimmune disease all point toward the acquired form. Testing for antibodies against VWF can confirm an immune-mediated mechanism when present.
Treatment Differences
Because the causes are different, the treatments diverge in important ways. Inherited VWD is managed by replacing or boosting VWF levels, either with medications that stimulate the body to release stored VWF or with clotting factor concentrates.
For the autoimmune-driven acquired form, the goal shifts to suppressing the immune attack. High-dose intravenous immunoglobulin (IVIg) is one of the primary therapies. In published cases, five-day courses of IVIg have led to complete cessation of bleeding, with hemoglobin levels stabilizing and VWF activity rebounding. Corticosteroids and other immunosuppressive drugs are also used. In severe or resistant cases, plasmapheresis (filtering the blood to remove the offending antibodies) may be combined with IVIg and clotting factor replacement. Treating the underlying condition, whether it is a lymphoproliferative disorder, thyroid disease, or another trigger, is equally important and can sometimes resolve the bleeding problem entirely.